Alpha-1 Canada’s mission is to provide information, education and support to Canadians affected by alpha-1 antitrypsin deficiency; inform and educate the medical community about alpha-1 antitrypsin deficiency; and generate broad awareness about this genetic liver, lung and skin disease.
Alpha-1 antitrypsin deficiency which is also known as alpha-1, A1AD and AATD, is a rare inherited genetic disorder that can affect the liver, lungs and skin.
Baxter International Inc. acquires exclusive right to distribute Kamada’s Glassia™ alpha-1 augmentation therapy in Canada
Our 2010 Annual General Meeting was June 24th, 2010 by telephone conference call.
Click here for details and documents.
Update on Testing for Alpha-1 Antitrypsin Deficiency in Canada
Listen to the podcast of Dr. Kenneth Chapman answering the question, "How do I get the best treatment for my (lung involved) Alpha-1?" Total length is about 1 hour.
This web site is made possible, in part, through an unrestricted educational grant provided by
© Alpha-1 Canada
Powered by Wild Apricot - Membership management database, online event registration,integrated website for associations, clubs, charities and other non-profits.
Site optimisé par Wild Apricot - base de données pour la gestion des adhésions, inscription en ligne aux événements,sites Web intégrés pour les associations les clubs, les organismes de bienfaisance et d'autres types d'organismes sans but lucratif.